Evidence map›Paper›PMID 36341188›Full record

ArticleIJU case reports2022

Successful radiofrequency ablation of liver metastases from prostate cancer.

Daichi Hino, Takahiro Sugano, Mika Kino, Takako Nakata, Hiroki Kito, Masafumi Inoue, Hajime Fujie, Koichiro Akakura

Open access · goldAbstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in IJU case reports, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.3field-weighted citation impact, top 41% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 2 citations in OpenAlex.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 1 institution in 1 country.

Daichi HinoDepartment of Urology, Pathology, Gastroenterology Japan Community Health-Care Organization Tokyo Shinjuku Medical Center Tokyo Japan.ORCID https://orcid.org/0000-0002-9045-7623
Takahiro SuganoDepartment of Urology, Pathology, Gastroenterology Japan Community Health-Care Organization Tokyo Shinjuku Medical Center Tokyo Japan.
Mika KinoDepartment of Urology, Pathology, Gastroenterology Japan Community Health-Care Organization Tokyo Shinjuku Medical Center Tokyo Japan.
Takako NakataDepartment of Urology, Pathology, Gastroenterology Japan Community Health-Care Organization Tokyo Shinjuku Medical Center Tokyo Japan.
Hiroki KitoDepartment of Urology, Pathology, Gastroenterology Japan Community Health-Care Organization Tokyo Shinjuku Medical Center Tokyo Japan.
Masafumi InoueDepartment of Urology, Pathology, Gastroenterology Japan Community Health-Care Organization Tokyo Shinjuku Medical Center Tokyo Japan.
Hajime FujieDepartment of Urology, Pathology, Gastroenterology Japan Community Health-Care Organization Tokyo Shinjuku Medical Center Tokyo Japan.
Koichiro AkakuraDepartment of Urology, Pathology, Gastroenterology Japan Community Health-Care Organization Tokyo Shinjuku Medical Center Tokyo Japan.
Tokyo Yamate Medical Center · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: Patients with liver metastases from prostate cancer show poor prognosis. We performed metastases-directed therapy using radiofrequency ablation of liver metastases in an attempt to improve the prognosis in a patient with metastatic prostate cancer. Case presentation: We present the case of a 66-year-old man who was treated for metastatic castration-resistant prostate cancer. Evaluation showed isolated liver metastases together with elevated serum prostate-specific antigen levels. We performed metastases-directed therapy using radiofrequency ablation of the liver tumor. The patient showed no recurrent liver metastases for 42 months and survived for 66 months after diagnosis of metastatic prostate cancer. Conclusion: To our knowledge, this is the first report that describes radiofrequency ablation of liver metastases from prostate cancer. This procedure may be a useful therapeutic option for metastases-directed therapy in patients with liver metastases from prostate cancer.

Indexed as

liver metastasismetastases‐directed therapyprostate cancerradiofrequency ablation

Identifiers

PMID36341188
PMCPMC9626322
OpenAlexW4289884624

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.